- Home
- ASG vs STRO Comparison
ASG vs STRO Comparison
Compare ASG & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASG | STRO |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 332.8M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASG | STRO |
|---|---|---|
| Price | $5.01 | $17.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 210.6K | 207.3K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.55 | $0.72 |
| 52 Week High | $5.69 | $43.85 |
Technical Indicators
Market Signals| Indicator | ASG | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 26.11 |
| Support Level | $4.98 | $10.34 |
| Resistance Level | $5.40 | $17.33 |
| Average True Range (ATR) | 0.05 | 0.99 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 9.38 | 9.16 |
Price Performance
Historical ComparisonAbout ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.